{"schema_version":"secwatch.filing_event.v1","accession":"0001906324-24-000048","form_type":"8-K","ticker":"QDEL","cik":"0001906324","company_name":"QuidelOrtho Corp","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.322682+00:00","generated_at":"2026-05-30T03:56:01.627716+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"QuidelOrtho Q3 GAAP net loss $20M ($0.30 EPS); revenue $727M; reinstates 2024 guidance","bullets":["Revenue $727M vs $744M YoY; Labs revenue grew 4% as reported (5% constant currency).","GAAP net loss $20M ($0.30 diluted EPS) vs loss $13M ($0.19) prior year; GAAP operating margin 2%.","Adjusted EBITDA margin 23.5%, up 80 bps; GAAP operating expenses down $13M to $242M.","Company reinstated 2024 financial guidance after withdrawing prior outlook.","Integration-related charges of $37M; new CTO and CHRO appointed."],"urls":{"canonical":"https://secwatch.observer/filing/0001906324-24-000048","json":"https://secwatch.observer/filing/0001906324-24-000048.json","markdown":"https://secwatch.observer/filing/0001906324-24-000048.md","text":"https://secwatch.observer/filing/0001906324-24-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1906324/000190632424000048/0001906324-24-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1906324/000190632424000048/qdel-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:56:01.627716+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}